目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Growth forecast
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 RESEARCH ASSUMPTIONS
2.5.1 PARAMETRIC ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW
4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024
4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX
4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing geriatric population and subsequent rise in chronic diseases
5.2.1.2 Growing awareness of early disease diagnosis in emerging economies
5.2.1.3 Emergence of rapid PoC technologies and rising adoption of automated analyzers
5.2.1.4 Growing preference for personalized medicines
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 Stringent regulatory requirements
5.2.2.3 High cost of diagnostic equipment
5.2.3 OPPORTUNITIES
5.2.3.1 Introduction of disease-specific biomarkers and tests
5.2.3.2 Increasing significance of companion diagnostics
5.2.3.3 Growth opportunities in developing countries
5.2.3.4 Improvements in immunoassay diagnostic technologies
5.2.3.5 Digitalization trend
5.2.4 CHALLENGES
5.2.4.1 Operational barriers
5.2.4.2 Data privacy and cybersecurity risks
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.4.3 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 RAW MATERIAL SUPPLIERS
5.5.3 MANUFACTURING
5.5.4 DISTRIBUTION, MARKETING, AND SALES
5.5.5 RETAILERS
5.5.6 POST-SALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Immunohistochemistry
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 382200
5.11.2 EXPORT DATA FOR HS CODE 382200
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE
5.13.2 CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN COMPETITIVE INDIAN MARKET
5.13.3 CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 REGULATORY FRAMEWORK
5.15.1 NORTH AMERICA
5.15.1.1 US
5.15.1.2 Canada
5.15.2 EUROPE
5.15.3 ASIA PACIFIC
5.15.3.1 Japan
5.15.3.2 China
5.15.3.3 India
5.15.3.4 South Korea
5.15.3.5 Indonesia
5.15.3.6 Russia
5.15.4 MIDDLE EAST & AFRICA
5.15.4.1 Saudi Arabia
5.15.4.2 Africa
5.15.5 LATIN AMERICA
5.15.5.1 Mexico
5.15.5.2 Brazil
5.16 PORTER'S FIVE FORCES ANALYSIS
5.16.1 BARGAINING POWER OF SUPPLIERS
5.16.2 BARGAINING POWER OF BUYERS
5.16.3 THREAT OF NEW ENTRANTS
5.16.4 THREAT OF SUBSTITUTES
5.16.5 INTENSITY OF COMPETITIVE RIVALRY
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS
5.19 INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES
5.20 GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING
5.21 IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET
5.21.1 INTRODUCTION
5.21.2 MARKET POTENTIAL OF AI IN IVD DEVICES
5.21.3 AI USE CASES
5.21.4 KEY COMPANIES IMPLEMENTING AI
5.21.5 FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET

6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.2.1 RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH
6.3 INSTRUMENTS
6.3.1 GROWING TREND OF AUTOMATION TO DRIVE MARKET
6.4 DATA MANAGEMENT SOFTWARE & SERVICES
6.4.1 INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH

7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAYS
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
7.2.1.1 Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.2.1 Need for minimal human intervention to support growth
7.2.3 IMMUNOFLUORESCENCE ASSAYS
7.2.3.1 Growing introduction of innovative diagnostic platforms to drive market
7.2.4 RAPID TESTS
7.2.4.1 Need for rapid diagnostic tests to expedite growth
7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
7.2.5.1 Need for early detection and monitoring of immune-related disorders to amplify growth
7.2.6 WESTERN BLOTTING
7.2.6.1 Increasing focus on biomarker discovery and personalized treatment to advance growth
7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES
7.3 CLINICAL CHEMISTRY
7.3.1 BASIC METABOLIC PANELS
7.3.1.1 Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth
7.3.2 LIVER PANELS
7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to foster growth
7.3.3 RENAL PROFILES
7.3.3.1 Growing awareness for preventive health check-ups to boost market
7.3.4 LIPID PROFILES
7.3.4.1 Rising prevalence of obesity to accelerate growth
7.3.5 THYROID FUNCTION PROFILES
7.3.5.1 High incidence of thyroid-related disorders to support growth
7.3.6 ELECTROLYTE PANELS
7.3.6.1 Growing shift toward home care and remote patient monitoring to fuel market
7.3.7 SPECIALTY CHEMICAL TESTS
7.3.7.1 Rising demand for specialized tests to contribute to growth
7.4 MOLECULAR DIAGNOSTICS
7.4.1 POLYMERASE CHAIN REACTION
7.4.1.1 High accuracy and speed in detecting pathogens to aid growth
7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
7.4.2.1 Growing focus on rapid, onsite molecular diagnostics to propel market
7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
7.4.3.1 Growing applications in research, drug discovery, and molecular diagnostics to boost market
7.4.4 IN SITU HYBRIDIZATION
7.4.4.1 Rising prevalence of cancer and genetic disorders to assist growth
7.4.5 DNA MICROARRAYS
7.4.5.1 High resolution and throughput capabilities to favor growth
7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
7.5 GLUCOSE MONITORING
7.5.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH
7.6 HEMATOLOGY
7.6.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET
7.7 MICROBIOLOGY
7.7.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH
7.8 COAGULATION & HEMOSTASIS
7.8.1 GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET
7.9 BLOOD GAS ANALYZERS
7.9.1 GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET
7.10 URINALYSIS
7.10.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH
7.11 CHROMATOGRAPHY & MASS SPECTROMETRY
7.11.1 INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH

8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN
8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA SPECIMENS
8.2.1 GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET
8.3 SALIVA SPECIMENS
8.3.1 GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TO BOOST MARKET
8.4 URINE SPECIMENS
8.4.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH
8.5 OTHER SPECIMENS

9 IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING
9.1 INTRODUCTION
9.2 LABORATORY TESTS
9.2.1 INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH
9.3 POINT-OF-CARE TESTS
9.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH

10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 INFECTIOUS DISEASES
10.2.1 INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH
10.3 ONCOLOGY
10.3.1 RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH
10.4 ENDOCRINOLOGY
10.4.1 INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH
10.5 CARDIOLOGY
10.5.1 GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET
10.6 BLOOD SCREENING
10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH
10.7 GENETIC TESTING
10.7.1 INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH
10.8 AUTOIMMUNE DISEASES
10.8.1 RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH
10.9 ALLERGY DIAGNOSTICS
10.9.1 INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH
10.10 DRUG MONITORING & TESTING
10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH
10.11 BONE & MINERAL DISORDERS
10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET
10.12 COAGULATION TESTING
10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH
10.13 BLOOD GROUP TYPING
10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH
10.14 OTHER APPLICATIONS

11 IN VITRO DIAGNOSTICS MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH
11.3 CLINICAL LABORATORIES
11.3.1 LARGE REFERENCE LABORATORIES
11.3.1.1 Growing test volume and complexity of diagnostic testing to propel market
11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES
11.3.2.1 Increasing shift toward community-based and point-of-care settings to foster growth
11.4 BLOOD BANKS
11.4.1 NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH
11.5 HOME CARE SETTINGS
11.5.1 GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET
11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.6.1 INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET
11.7 ACADEMIC INSTITUTES
11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH
11.8 OTHER END USERS

12 IN VITRO DIAGNOSTICS MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market
12.2.3 CANADA
12.2.3.1 Favorable funding initiatives for early disease diagnosis to fuel market
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Increasing investments in clinical diagnostics research to aid growth
12.3.3 FRANCE
12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market
12.3.4 UK
12.3.4.1 Rising adoption of genome-based testing to encourage growth
12.3.5 ITALY
12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to boost market
12.3.6 SPAIN
12.3.6.1 Increasing adoption of technologically advanced immunoassay systems to expedite growth
12.3.7 RUSSIA
12.3.7.1 High incidence of respiratory infectious diseases to boost market
12.3.8 SWITZERLAND
12.3.8.1 Growing prevalence of chronic diseases to propel market
12.3.9 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 JAPAN
12.4.2.1 Increasing research investments for immunoassays to encourage growth
12.4.3 CHINA
12.4.3.1 Growing focus on preventive care to boost market
12.4.4 INDIA
12.4.4.1 Rising incidence of diabetes and cancer to augment growth
12.4.5 SOUTH KOREA
12.4.5.1 Rising healthcare spending for innovative IVD technologies to amplify growth
12.4.6 AUSTRALIA
12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market
12.4.7 SINGAPORE
12.4.7.1 Rising technological advancements and automation to stimulate growth
12.4.8 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Rising prevalence of diabetes to sustain growth
12.5.3 MEXICO
12.5.3.1 Growing establishment of clinical laboratories to fuel market
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET
12.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
12.7 GCC COUNTRIES
12.7.1 GCC COUNTRIES: MACROECONOMIC OUTLOOK
12.7.2 SAUDI ARABIA
12.7.2.1 Rising government healthcare expenditure to boost market
12.7.3 UAE
12.7.3.1 Improvements in healthcare infrastructure to support growth
12.7.4 OTHER GCC COUNTRIES

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
13.4 REVENUE ANALYSIS, 2022-2024
13.5 MARKET SHARE ANALYSIS, 2024
13.6 COMPANY VALUATION AND FINANCIAL METRICS
13.7 BRAND/PRODUCT COMPARISON
13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.8.1 STARS
13.8.2 EMERGING LEADERS
13.8.3 PERVASIVE PLAYERS
13.8.4 PARTICIPANTS
13.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.8.5.1 Company footprint
13.8.5.2 Region footprint
13.8.5.3 Product & service footprint
13.8.5.4 Technology footprint
13.8.5.5 End-user footprint
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.9.1 PROGRESSIVE COMPANIES
13.9.2 RESPONSIVE COMPANIES
13.9.3 DYNAMIC COMPANIES
13.9.4 STARTING BLOCKS
13.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.9.5.1 Detailed list of key startups/SMEs
13.9.5.2 Competitive benchmarking of key startups/SMEs
13.10 COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES AND APPROVALS
13.10.2 DEALS
13.10.3 EXPANSIONS
13.11 POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET
13.11.1 PRODUCT LAUNCHES AND APPROVALS
13.11.2 DEALS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 DANAHER
14.1.1.1 Business overview
14.1.1.2 Products/Services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches and approvals
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 F. HOFFMANN-LA ROCHE LTD
14.1.2.1 Business overview
14.1.2.2 Products/Services offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches and approvals
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 ABBOTT
14.1.3.1 Business overview
14.1.3.2 Products/Services offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weakness and competitive threats
14.1.4 SIEMENS HEALTHINEERS AG
14.1.4.1 Business overview
14.1.4.2 Products/Services offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.3.3 Expansions
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 THERMO FISHER SCIENTIFIC INC.
14.1.5.1 Business overview
14.1.5.2 Products/Services offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.3.3 Expansions
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 ILLUMINA, INC.
14.1.6.1 Business overview
14.1.6.2 Products/Services offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.6.3.3 Expansions
14.1.6.3.4 Other developments
14.1.7 HOLOGIC, INC.
14.1.7.1 Business overview
14.1.7.2 Products/Services offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Expansions
14.1.8 BIO-RAD LABORATORIES, INC.
14.1.8.1 Business overview
14.1.8.2 Products/Services offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches and approvals
14.1.8.3.2 Deals
14.1.9 BIOMERIEUX
14.1.9.1 Business overview
14.1.9.2 Products/Services offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.9.3.2 Deals
14.1.9.3.3 Expansions
14.1.10 SYSMEX CORPORATION
14.1.10.1 Business overview
14.1.10.2 Products/Services offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.10.3.3 Expansions
14.1.11 REVVITY
14.1.11.1 Business overview
14.1.11.2 Products/Services offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches and approvals
14.1.11.3.2 Deals
14.1.11.3.3 Other developments
14.1.12 BECTON, DICKINSON AND COMPANY
14.1.12.1 Business overview
14.1.12.2 Products/Services offered
14.1.12.3 Recent developments
14.1.12.3.1 Product launches and approvals
14.1.12.3.2 Deals
14.1.12.3.3 Expansions
14.1.13 AGILENT TECHNOLOGIES, INC.
14.1.13.1 Business overview
14.1.13.2 Products/Services offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.13.3.3 Other developments
14.1.14 QIAGEN
14.1.14.1 Business overview
14.1.14.2 Products/Services offered
14.1.14.3 Recent developments
14.1.14.3.1 Product launches and approvals
14.1.14.3.2 Deals
14.1.15 DIASORIN S.P.A.
14.1.15.1 Business overview
14.1.15.2 Products/Services offered
14.1.15.3 Recent developments
14.1.15.3.1 Product launches and approvals
14.1.15.3.2 Deals
14.1.16 GRIFOLS, S.A.
14.1.16.1 Business overview
14.1.16.2 Products/Services offered
14.1.16.3 Recent developments
14.1.16.3.1 Product launches and approvals
14.1.16.3.2 Deals
14.1.17 WERFEN
14.1.17.1 Business overview
14.1.17.2 Products/Services offered
14.1.17.2.1 Deals
14.1.17.2.2 Expansions
14.1.18 QUIDELORTHO CORPORATION
14.1.18.1 Business overview
14.1.18.2 Products/Services offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.18.3.2 Deals
14.1.18.3.3 Expansions
14.2 OTHER PLAYERS
14.2.1 DEVYSER
14.2.2 BIOSYNEX SA
14.2.3 SURMODICS, INC.
14.2.4 MENARINI SILICON BIOSYSTEMS
14.2.5 SPEEDX PTY. LTD.
14.2.6 GENSPEED BIOTECH GMBH
14.2.7 MERCK KGAA
14.2.8 CARIS LIFE SCIENCES
14.2.9 ARKRAY, INC.
14.2.10 ACCELERATE DIAGNOSTICS, INC.
14.2.11 CELLABS
14.2.12 J. MITRA & CO. PVT. LTD.
14.2.13 EPITOPE DIAGNOSTICS, INC.
14.2.14 BOSTER BIOLOGICAL TECHNOLOGY
14.2.15 ENZO BIOCHEM INC.
14.2.16 GENETIC SIGNATURES
14.2.17 SAVYON DIAGNOSTICS
14.2.18 TRIVITRON HEALTHCARE
14.2.19 MDXHEALTH
14.2.20 CREATIVE DIAGNOSTICS
14.2.21 INBIOS INTERNATIONAL, INC.
14.2.22 MACCURA BIOTECHNOLOGY CO., LTD.
14.2.23 LUYE LIFE SCIENCES GROUP

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS